Cite

HARVARD Citation

    Judd, J. et al. (2017). Immune‐Related Adverse Events as a Biomarker in Non‐Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. Oncologist. pp. 1232-1237. [Online]. 
  
Back to record